In parallel with the incrementally less impressive results, the excitement for CK-18 as a NAFLD biomarker has tempered with each subsequent study, serving as an exemplar of the entire biomarker space. This evidence concerns the gene KRT18 and metabolic dysfunction-associated steatotic liver disease.